Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) Short Interest Down 28.6% in March

Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) was the target of a large drop in short interest during the month of March. As of March 15th, there was short interest totalling 500 shares, a drop of 28.6% from the February 28th total of 700 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average daily volume of 14,200 shares, the short-interest ratio is currently 0.0 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Tema Cardiovascular and Metabolics ETF stock. Sterling Investment Advisors Ltd. lifted its stake in Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) by 5.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 167,703 shares of the company’s stock after purchasing an additional 9,008 shares during the period. Tema Cardiovascular and Metabolics ETF comprises about 1.2% of Sterling Investment Advisors Ltd.’s investment portfolio, making the stock its 24th largest position. Sterling Investment Advisors Ltd. owned 7.29% of Tema Cardiovascular and Metabolics ETF worth $4,842,000 as of its most recent filing with the Securities and Exchange Commission.

Tema Cardiovascular and Metabolics ETF Price Performance

Shares of Tema Cardiovascular and Metabolics ETF stock traded up $0.01 on Friday, reaching $29.47. The company had a trading volume of 2,279 shares, compared to its average volume of 12,413. The firm’s 50-day moving average price is $30.13 and its two-hundred day moving average price is $31.39. Tema Cardiovascular and Metabolics ETF has a 1 year low of $28.56 and a 1 year high of $36.03. The firm has a market cap of $67.78 million, a price-to-earnings ratio of 30.61 and a beta of 0.93.

Tema Cardiovascular and Metabolics ETF Company Profile

The Tema Obesity & Cardiometabolic ETF (HRTS) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that concentrates on companies focused on the treatment of cardiovascular diseases and/or metabolic diseases from companies all around the world. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive.